# Compare the Efficacy and Safety of Rosuvastatin/Ezetimibe Combination Therapy Versus Rosuvastatin Monotherapy in Korean Patients With Left Ventricular Diastolic Dysfunction and Hyperlipidemia

> **NCT04433533** · PHASE4 · UNKNOWN · sponsor: **Yonsei University** · enrollment: 200 (estimated)

## Conditions studied

- Left Ventricular Diastolic Dysfunction
- Hyperlipidemias

## Interventions

- **DRUG:** Rosuvastatin 20
- **DRUG:** Rosuvamibe 10/10

## Key facts

- **NCT ID:** NCT04433533
- **Lead sponsor:** Yonsei University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-01-06
- **Primary completion:** 2023-06
- **Final completion:** 2023-12
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2021-01-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04433533

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04433533, "Compare the Efficacy and Safety of Rosuvastatin/Ezetimibe Combination Therapy Versus Rosuvastatin Monotherapy in Korean Patients With Left Ventricular Diastolic Dysfunction and Hyperlipidemia". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04433533. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*